Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Roche $295 million acquisition of LumiraDx's point of care technology platform
We are advising Roche on the acquisition
GSK exclusive license agreement for HS-20093 with Hansoh Pharma
We advised GSK on the transaction
Smith+Nephew acquisition of CartiHeal
We are advising Smith+Nephew on the acquisition
Forbion European Acquisition $138 million combination with enGene
We advised Forbion European Acquisition on its de-SPAC transaction
GSK exclusive license agreement for HS-20089 with Hansoh Pharma
We advised GSK on the transaction
GSK collaboration extension and new data licensing agreement with 23andMe
We advised GSK on the transaction
Roche $7.1 billion acquisition of Telavant and rights to RVT 3101 from Roivant
We are advising Roche on the acquisition
RayzeBio $358 million IPO
The stock is listed on the Nasdaq Global Market
SSI Strategy acquisition of NDA Group
We advised SSI Strategy on the acquisition